Suryavathi Viswanadhapalli

Assistant Professor

University of Texas Health Science Center at San Antonio

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Suryavathi Viswanadhapalli is an Assistant Professor at The University of Texas Health Science Center at San Antonio, USA. Her research primarily focuses on the signaling pathways in women's cancers, particularly concerning Midkine and LIF/LIFR, and their role as biomarker and therapeutic targets. Recent articles highlight her work on obesity-driven triple-negative breast cancer, ovarian cancer therapies, and innovative treatment strategies for various oncogenic signaling pathways.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (10)

Ratna Vadlamudi

Professor

UNITED STATES

View details

John Sanchez

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

UT Health San Antonio

UNITED STATES

View details

Gangadhara Reddy Sareddy

Assistant Professor

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Suryavathi Viswanadhapalli

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target

Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis

Novel LIPA-Targeted Therapy for Treating Ovarian Cancer

Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer

Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis

Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress

Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma

The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling

Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth

Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.

FASN inhibition as a potential treatment for endocrine-resistant breast cancer.

Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.

Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.

KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.

Collaborators (10)

Ratna Vadlamudi

John Sanchez

Aleksandra Gruslova

Huan Xie

Hui Yan

Siyuan Zheng

Dong Liang

Christoforos Thomas

Behnam Ebrahimi

Gangadhara Reddy Sareddy

Make your next move.